Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

doi:10.1093/ofid/ofab050

. 2021 Feb 1;8(2):ofab050.

doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel^{1

2}, David R Boulware³

Affiliations

¹ Golden Gate Fields Medical Clinic, Berkeley, California, USA.
² Enable Biosciences Inc, South San Francisco, California, USA.
³ University of Minnesota Medical School, Minneapolis, Minnesota, USA.

PMID: 33623808
PMCID: PMC7888564
DOI: 10.1093/ofid/ofab050

Free PMC article

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel et al. Open Forum Infect Dis. 2021.

Free PMC article

. 2021 Feb 1;8(2):ofab050.

doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.

Authors

David Seftel^{1

2}, David R Boulware³

Affiliations

¹ Golden Gate Fields Medical Clinic, Berkeley, California, USA.
² Enable Biosciences Inc, South San Francisco, California, USA.
³ University of Minnesota Medical School, Minneapolis, Minnesota, USA.

PMID: 33623808
PMCID: PMC7888564
DOI: 10.1093/ofid/ofab050

Abstract

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

Keywords: COVID-19; SARS-COV-2; cohort; coronavirus; fluvoxamine.

PubMed Disclaimer

Cited by

Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.
Scheim DE, Vottero P, Santin AD, Hirsh AG. Scheim DE, et al. Int J Mol Sci. 2023 Dec 1;24(23):17039. doi: 10.3390/ijms242317039. Int J Mol Sci. 2023. PMID: 38069362 Free PMC article. Review.
Effectiveness of antidepressants in improving the prognosis of COVID-19: A systematic review and meta-analysis.
Cobos-Campos R, de Lafuente-Moríñigo AS, Cordero-Guevara JA, Bermúdez-Ampudia C, Apiñaniz A, Parraza N. Cobos-Campos R, et al. Aten Primaria. 2024 Mar;56(3):102771. doi: 10.1016/j.aprim.2023.102771. Epub 2023 Nov 28. Aten Primaria. 2024. PMID: 38016405 Free PMC article.
Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19: A multicenter observational retrospective study.
Sánchez-Rico M, Edán-Sánchez A, Olfson M, Alvarado JM, Airagnes G, Rezaei K, Delcuze A, Peyre H, Limosin F, Hoertel N; AP-HP / Université Paris Cité / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, and “Entrepôt de Données de Santé” AP-HP Consortium. Sánchez-Rico M, et al. Eur Neuropsychopharmacol. 2023 Oct;75:93-104. doi: 10.1016/j.euroneuro.2023.06.005. Epub 2023 Jun 16. Eur Neuropsychopharmacol. 2023. PMID: 37713738 Free PMC article.
An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model.
Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan WY, Davidson EA, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder EA, Coppi A, Schulz W, Iwasaki A, Pierce RW, Cruz CSD, Desir GV, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis NS, Ko AI; Yale IMPACT Study Team; Thompson DC, Vasiliou V. Charkoftaki G, et al. Hum Genomics. 2023 Aug 29;17(1):80. doi: 10.1186/s40246-023-00521-4. Hum Genomics. 2023. PMID: 37641126 Free PMC article.
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.
Hoertel N, Rezaei K, Sánchez-Rico M, Delgado-Álvarez A, Kornhuber J, Gulbins E, Olfson M, Ouazana-Vedrines C, Carpinteiro A, Cougoule C, Becker KA, Alvarado JM, Limosin F, On Behalf Of The Ap-Hp/Université Paris Cité/Inserm Covid-Research Collaboration Ap-Hp Covid Cdr Initiative And Entrepôt de Données de Santé Ap-Hp Consortium. Hoertel N, et al. Pharmaceuticals (Basel). 2023 Aug 4;16(8):1107. doi: 10.3390/ph16081107. Pharmaceuticals (Basel). 2023. PMID: 37631022 Free PMC article.

See all "Cited by" articles

References

1. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: a randomized clinical trial. JAMA 2020; 324:2292–300. - PMC - PubMed
1. Rosen DA, Seki SM, Fernandez-Castaneda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 2019; 11: eaau5266. - PMC - PubMed
1. Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation 2020. doi: 10.1161/CIRCULATIONAHA.120.051718. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: a randomized clinical trial. JAMA 2020; 324:2292–300. - PMC - PubMed

[2] Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: a randomized clinical trial. JAMA 2020; 324:2292–300. - PMC - PubMed

[3] Rosen DA, Seki SM, Fernandez-Castaneda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 2019; 11: eaau5266. - PMC - PubMed

[4] Rosen DA, Seki SM, Fernandez-Castaneda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 2019; 11: eaau5266. - PMC - PubMed

[5] Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation 2020. doi: 10.1161/CIRCULATIONAHA.120.051718. - DOI - PubMed

[6] Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation 2020. doi: 10.1161/CIRCULATIONAHA.120.051718. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Affiliations

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Authors

Affiliations

Abstract

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous